Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 12/20 | 0.85 |
| ▸ | MAP4K2 | Q12851 | 12/20 | 0.85 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.85 |
| ▸ | FES | P07332 | 5/20 | 0.69 |
| ▸ | FER | P16591 | 5/20 | 0.69 |
| ▸ | MAP3K20 | Q9NYL2 | 5/20 | 0.69 |
| ▸ | CSK | P41240 | 5/20 | 0.69 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.69 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.69 |
| ▸ | ABL1 | P00519 | 3/20 | 0.69 |
| ▸ | RAF1 | P04049 | 3/20 | 0.69 |
| ▸ | LYN | P07948 | 3/20 | 0.69 |
| ▸ | SRC | P12931 | 3/20 | 0.69 |
| ▸ | EPHB2 | P29323 | 3/20 | 0.69 |
| ▸ | ABL2 | P42684 | 3/20 | 0.69 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.69 |
| ▸ | FLT3 | P36888 | 2/20 | 0.69 |
| ▸ | HCK | P08631 | 7/20 | 0.61 |
| ▸ | NR2C2 | P49116 | 7/20 | 0.61 |
| ▸ | GCK | P35557 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14690370 | 1.00 | MAP3K7 (0.85) | MAP3K7MAP4K2MAPK14FESFER | |
| SCHEMBL30692261 | 0.92 | MAP3K7 (1.00) | MAP3K7MAP4K2MAPK14FESFER | |
| SCHEMBL14690002 | 0.92 | MAP3K7 (1.00) | MAP3K7MAP4K2MAPK14FESFER | |
| SCHEMBL2848857 | 0.91 | MAPK14 (0.73) | MAP3K7MAP4K2MAPK14FESFER | |
| SCHEMBL3880675 | 0.86 | MAPK14 (0.71) | MAP3K7MAP4K2MAPK14FESFER | |
| SCHEMBL14690163 | 0.81 | MAP3K7 (1.00) | MAP3K7MAP4K2MAPK14FESFER | |
| SCHEMBL30692248 | 0.81 | MAP3K7 (1.00) | MAP3K7MAP4K2MAPK14FESFER | |
| SCHEMBL30692260 | 0.81 | MAP3K7 (1.00) | MAP3K7MAP4K2MAPK14FESFER | |
| SCHEMBL14689441 | 0.81 | MAP3K7 (1.00) | MAP3K7MAP4K2MAPK14FESFER | |
| SCHEMBL30912864 | 0.81 | MAP3K7 (1.00) | MAP3K7MAP4K2MAPK14FESFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11826365-B2 | Type II raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11826365-B2 | Type II raf kinase inhibitors | BRAF, RAF1, ARAF | MAP3K7 21/4885MAP4K2 24/4885MAPK14 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.